Once upon a time, Teladoc Health (TDOC) was a market darling. During the height of the pandemic, this telemedicine company experienced explosive business growth, with revenue and stock prices reaching incredibly high levels. However, this telemedicine specialist failed to sustain its growth momentum, and over the past five years, its stock has accumulated a decline of more than 90%. At the current price level, if Teladoc can re-establish its dominant position in the telemedicine market and significantly improve its financial performance, it could deliver astonishing returns over the next decade.
In the past few years, Teladoc’s financial performance has been consistently disappointing. Take the company’s first-quarter earnings as an example: revenue fell 2% year-over-year to $613.8 million. Although the net loss narrowed, with a loss of $0.36 per share, better than the loss of $0.53 per share in the same period last year, Teladoc recorded a large goodwill impairment charge in the first quarter of 2025, which negatively impacted net profit. The key issue is that Teladoc is still not profitable, and it remains unclear whether the business is organically and significantly improving.
Teladoc’s virtual therapy business, BetterHelp, once an important growth driver, has been in decline for many years. In the first quarter, BetterHelp’s revenue and number of paying users both fell 9% year-over-year. One bright spot in the financial data is the international expansion effort: international revenue grew 17% year-over-year to $122.3 million during the period. But overall, Teladoc’s performance is far from ideal. The company faces intense competition in the telemedicine market, from both new entrants and established healthcare networks with deep ecosystems that have built their own virtual health platforms. Additionally, the trend of patients returning to in-person care has also posed challenges for Teladoc.
It should be noted that Teladoc has made some progress. BetterHelp now accepts health insurance in some states, which could help reverse the recent downturn in this business segment. Teladoc expects the annualized revenue run rate for insurance-covered BetterHelp services to be $75 million, and it plans to reach at least $125 million by the end of the year. Meanwhile, continued international expansion is expected to boost the company’s revenue, as the international business accounts for a growing share. Furthermore, Teladoc is leveraging artificial intelligence, planning to launch a range of AI products and tools on its platform to increase revenue.
However, these measures are not enough to lift the company out of its difficulties. Differences between countries in prescription regulations and the many medical services offered on the platform, combined with uneven insurance coverage across countries, mean that Teladoc may need to invest significant time and money before its international operations can become a meaningful source of profit.
